Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 12, 2026

Applied Materials AMAT Q1 2026 Earnings Transcript

View original at nasdaq.com
Applied Materials AMAT Q1 2026 Earnings Transcript Image source: The Motley Fool. Date Thursday, February 12, 2026 at 4:30 p.m…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Gross margin will reflect product and customer mix, as well as continued improvements in productivity and cost, expected to trend favorably as mix normalizes and cost actions take hold

    80% confidence
  • Services margins are stable to improving, supported by higher attachment, software content, and productivity initiatives

    80% confidence
  • Applied Materials is well positioned for gate-all-around and backside power transitions with broad suite of solutions

    80% confidence
  • Company has seen some timing shifts typical for the industry, but no material cancellations; overall demand signals remain constructive

    80% confidence
  • Company has made progress diversifying suppliers, increasing dual-sourcing, and localizing critical components

    80% confidence
  • Company continues to comply with all regulations; demand in China remains mixed by segment, with mature nodes steady and certain leading-edge areas impacted by restrictions

    80% confidence
  • Integrated solutions help customers improve line-edge roughness, CD control, and defectivity, critical as EUV moves deeper into HVM and to higher NA

    80% confidence
  • Company is seeing strong pull for tools supporting HBM, including patterning, dielectric deposition, and advanced packaging steps like hybrid bonding and TSV-related processes

    80% confidence
  • EUV scaling increases requirements for patterning adjacencies, hard mask engineering, clean, and metrology/inspection

    80% confidence
  • Near term, OpEx will grow modestly, below the pace of revenue, to drive operating leverage while prioritizing R&D and customer support

    80% confidence
  • Customers continue to accelerate node migrations and new 3D scaling approaches, expanding opportunity for differentiated materials engineering portfolio

    80% confidence
  • Visibility for HBM-related tools extends through multiple quarters given customers' capacity plans

    80% confidence
  • Both DRAM and NAND segments expected to grow through the year, with DRAM outpacing NAND near term

    80% confidence
  • Company continues to expand capacity in critical product lines and investing in supply resiliency, with lead times improving

    80% confidence
  • Applied Materials differentiates with a comprehensive toolset across wafer-level packaging, hybrid bonding, and inspection/metrology

    80% confidence
  • Company is investing in automation and remote capabilities to enhance uptime and yield for customers

    80% confidence
  • Company expects to continue repurchasing shares at a steady pace while funding strategic investments

    80% confidence
  • Metrology and inspection are growing as process complexity increases, with e-beam and optical platforms gaining traction

    80% confidence
  • Applied Materials delivered solid results in Q1 2026, driven by strong demand across AI, foundry-logic, and memory

    80% confidence
  • DRAM WFE is leading the recovery, particularly with HBM-driven investments, while NAND is improving at a slower pace

    80% confidence
  • ICAPS demand remains healthy, supporting power, automotive, and industrial applications, though growth is moderating from peak levels

    80% confidence
  • Backlog remains elevated with a book-to-bill around unity; working through backlog as supply improves

    80% confidence
  • Services mix continues to shift toward performance-based contracts

    80% confidence
  • Applied Materials returned capital to shareholders through repurchases and dividends, and continues to invest in R&D and capacity to support long-term growth

    80% confidence
  • Foundry-logic remains healthy with strength at leading nodes, while memory is improving, led by DRAM and HBM-related investments

    80% confidence
  • R&D priorities include gate-all-around, backside power, advanced packaging, EUV adjacencies, new materials for scaling, and expanding metrology/inspection capabilities with AI-driven analytics

    80% confidence
  • OpEx will grow at a measured pace focused on R&D and customer enablement, with discipline on overhead

    80% confidence
  • Supply chain actions improve resiliency, reduce lead times, and support compliance with evolving trade regulations

    80% confidence
  • Services growth is supported by expanding installed base, higher attachment to performance-based agreements, and analytics-driven optimization

    80% confidence
  • Company closely monitors regulatory developments, including CFIUS-related matters; outlook reflects current regulatory environment with appropriate assumptions incorporated

    80% confidence

Data points we hold from this source

Applied Materials, Inc. · book to bill ratio1.0 ratio
Applied Materials, Inc. · backlogelevated qualitative
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com
Applied Materials AMAT Q1 2026 Earnings Transcript — Source | Via News | ViaNews Market